Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03546491 · ClinicalTrials.gov registry record · Phase 3
Evaluate Dental Plaque Benefit of a Preventive Treatment Gel
A Phase 3 study, sponsored by Procter and Gamble.
- Completed
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
NCT03546491: Completed Phase 3 study, sponsored by Procter and Gamble.
NCT03546491 is a Phase 3 study that has completed, run by Procter and Gamble. The registered enrollment target is 32 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03546491, a Phase 3 study, has completed, sponsored by Procter and Gamble.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate anti-plaque efficacy of a preventive treatment gel in a modified 4-day plaque model.
Primary Outcome
The Turesky Modified Quigley-Hein Index was scored on six surfaces (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual and mesiolingual) to assess plaque on all gradable teeth. Whole mouth average plaque scores were calculated for each subject and tooth surfaces by totaling the scores and dividing by the number of gradable sites examined. the scoring criteria is below; (0) No Plaque; (1) Separate flecks of plaque at the cervical margin; (2) A thin, continuous band of plaque (up to 1 m
Interventions
- DRUG Preventive Gel
- DRUG Marketed Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-05-08 |
| Est. Completion | 2018-06-22 |
| Phase | Phase 3 |
What the finished NCT03546491 record still lists
NCT03546491 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Preventive Gel is the first listed.
NCT03546491 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03546491 about?
NCT03546491 is a clinical study titled "Evaluate Dental Plaque Benefit of a Preventive Treatment Gel". The objective of the study is to evaluate anti-plaque efficacy of a preventive treatment gel in a modified 4-day plaque model.
What is the current status of trial NCT03546491?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2018-05-08. Estimated completion is 2018-06-22.
What interventions are being tested in trial NCT03546491?
The interventions under investigation include: Preventive Gel (DRUG), Marketed Control (DRUG).
Who is sponsoring clinical trial NCT03546491?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03546491's enrollment target sits among peer trials
32 1909th of 2000 higher than 87 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI